Skip to main content
Imunon, Inc. logo

Imunon, Inc. — Investor Relations & Filings

Ticker · IMNN ISIN · US15117N6022 US Manufacturing
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2026-06-04 Capital/Financing Update
Country US United States of America
Listing US IMNN

About Imunon, Inc.

https://imunon.com/

Imunon, Inc. is a clinical-stage biotechnology company that develops novel immunotherapies and DNA-based vaccines. The company's core focus is on creating treatments for challenging conditions, including cancer and infectious diseases, by harnessing the patient's immune system. Its proprietary technology platforms are centered on immunology and nucleic acid-based therapies. The lead candidate in its pipeline is IMNN-001, a DNA-based immunotherapy in clinical development for advanced ovarian cancer. Imunon oversees the complete drug development lifecycle, from initial research and discovery to manufacturing in its in-house GMP-compliant facility.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 87% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, primarily describing the entry into a material securities purchase agreement, issuance of Series A Preferred Stock and secured promissory notes, and the associated financing terms and proceeds. This is a clear update on the company’s fundraising and capital structure changes. Under the FinancialReports taxonomy, this corresponds to a Capital/Financing Update (CAP), not merely a regulatory announcement or press release. Therefore it should be classified as CAP.
2026-06-04 English
10-Q - Imunon, Inc. (0000749647) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-12 English
8-K - Imunon, Inc. (0000749647) (Filer)
Regulatory Filings Classification · 95% confidence The document is a U.S. SEC Form 8-K “Current Report” under the Exchange Act, furnishing an earnings press release as Exhibit 99.1. It is a regulatory compliance filing rather than the full earnings release or financial report itself. Under the classification rules, standalone SEC filings and compliance disclosures that do not fit other categories are classified as Regulatory Filings (RNS).
2026-05-12 English
ARS
Annual Report FY 2025
2026-05-04 English
8-K - Imunon, Inc. (0000749647) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 8-K (“Current Report”) filed under Item 5.02 detailing change‐of‐control compensation agreements for certain executive officers. It does not present full financial statements (not an Annual or Interim Report), nor is it an earnings release, proxy statement, or other more specialized filing. It is a regulatory filing that does not fit the other, more specific categories, so it is classified as a general Regulatory Filing (RNS).
2026-05-04 English
DEF 14A - Imunon, Inc. (0000749647) (Filer)
Proxy Solicitation & Information Statement
2026-05-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.